Ladenburg analyst Michael Higgins maintained a Buy rating on Savara Inc (SVRA) today and set a price target of $21. The company’s shares opened today at $7.42, close to its 52-week low of $6.21.
According to TipRanks.com, Higgins has currently no stars on a ranking scale of 0-5 stars, with an average return of -9.4% and a 31.4% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Rhythm Pharmaceuticals Inc, Paratek Pharmaceuticals, and Zynerba Pharmaceuticals.
Currently, the analyst consensus on Savara Inc is a Strong Buy with an average price target of $19.75, a 166.2% upside from current levels. In a report issued on March 25, Canaccord Genuity also maintained a Buy rating on the stock with a $22 price target.
See today’s analyst top recommended stocks >>
Based on Savara Inc’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $10.51 million. In comparison, last year the company had a GAAP net loss of $26.85 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Savara, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its products include AeroVanc, Molgradex, GM-CSF, and Aironite. The company was founded on April 27, 2017 and is headquartered in Austin, TX.
